X4 Pharmaceuticals, Inc. - Common Stock —— 现金流量表 (NASDAQ:XFOR) | MetaTrader

展开完整图表完整图表

Financials

概览声明统计

每季度年度

经营活动产生的现金 -58.82 M-70.91 M-77.1 M-96.51 M-130.9 M-85.62 M -92.85 M 投资活动产生的现金 -1.36 M-615 K-103 K-14.88 M66.99 M8.15 M 30.54 M 融资活动产生的现金 12.39 M74.25 M117.23 M88.52 M20.29 M238.63 M 238.63 M 自由现金流 -60.18 M-71.52 M-77.2 M-96.57 M-130.9 M-85.62 M -92.85 M

新闻

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Stifel重申X4 Pharmaceuticals股票评级,临床试验进展顺利

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

X4 Pharmaceuticals在Leerink全球医疗保健会议上宣布战略转向罕见血液病领域

X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology

Guggenheim initiates X4 Pharmaceuticals stock with buy rating

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

欧洲药品管理局专家组支持mavorixafor用于超罕见WHIM综合征治疗